株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尋常性乾癬 : パイプライン分析

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 199662
出版日 ページ情報 英文 294 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
尋常性乾癬 : パイプライン分析 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016
出版日: 2016年10月19日 ページ情報: 英文 294 Pages
概要

尋常性乾癬とは、慢性の、再発する、炎症性の皮膚疾患です。尋常性乾癬の頻度・重症度は喫煙、日光暴露、アルゴリズム、およびHIV感染といった環境的要因に影響されます。尋常性乾癬の症状には、銀色の鱗屑で覆われた皮膚の紅斑、小さな鱗屑、出血の可能性を伴う乾燥し砕けた皮膚、灼熱感、痒み、ヒリヒリする痛み、肥厚、爪のへこみまたは溝、関節腫脹、関節硬化、および頭皮のふけのような鱗屑などがあります。尋常性乾癬は主に皮膚科専門医の診察によって診断され、診断のための血液検査またはラボ検査はありません。

当レポートでは、尋常性乾癬に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

尋常性乾癬;概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

治療薬開発に従事している企業

  • 3SBio Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Avesthagen Limited
  • Avexxin AS
  • BIOCAD
  • Biocon Limited
  • Bionovis SA
  • Can-Fite BioPharma Ltd.
  • Celgene Corporation
  • Celltrion, Inc.
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hetero Drugs Limited
  • Idera Pharmaceuticals, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • 協和発酵キリン
  • LEO Pharma A/S
  • Lipidor AB
  • Mabion SA
  • Mabtech Limited
  • マルホ
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Promius Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • TetraLogic Pharmaceuticals
  • Therapeutic Proteins International, LLC
  • UCB S.A.
  • Valeant Pharmaceuticals International, Inc.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (betamethasone dipropionate + calcipotriene)
  • (calcipotriene + betamethasone dipropionate)
  • (calcipotriene + betamethasone)
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • adalimumab biosimilar
  • AM-001
  • AVX-001
  • betamethasone valerate + maxacalcitol
  • bimekizumab
  • bleselumab
  • brodalumab
  • calcipotriene
  • CC-90005
  • CT-327
  • dalazatide
  • DFD-01
  • DFD-06
  • dimethyl fumarate
  • DLX-105
  • DNX-114
  • DNX-514
  • DRM-02
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • etanercept biosimilar
  • GK-664S
  • GRMD-02
  • GSK-2981278
  • guselkumab
  • IDP-118
  • IDP-122
  • IMO-84001
  • IMP-731
  • infliximab biobetter
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • infliximab biosimilar
  • INV-103
  • KD-025
  • LEO-32731
  • LP-0113
  • M-7040
  • MOL-4239
  • MOL-4249
  • pefcalcitol
  • PF-04965842
  • PF-06700841
  • PH-10
  • piclidenoson
  • RTU-1096
  • SHP-141
  • tofacitinib
  • toreforant tartrate
  • UCB-5857
  • ustekinumab biosimilar

最新パイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8559IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape.

Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris).

Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Plaque Psoriasis (Psoriasis Vulgaris) Overview
  • Therapeutics Development
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance
  • Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies
  • Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development
  • Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment
  • Drug Profiles
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products
  • Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016
  • Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top